Haemophilia Trial, Recruiting NCT06222697 Sponsor: Bayer Condition: Haemophilia
Back to Haemophilia

Haemophilia Trial, Recruiting

NCT06222697
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 12 years old or older and have hemophilia A
  • You have previously been treated with Factor VIII (a clotting protein) concentrates, either from plasma or made in a lab
  • You are already being treated with, or your doctor has decided to start you on, a medicine called Jivi (damoctocog alfa pegol) — this could be taken as needed or on a regular schedule
  • You (or your parent/legal guardian if appropriate) are able to give written consent to participate

Who may not be able to join:

  • You have a known allergy or sensitivity to Jivi or any of its ingredients, including mouse or hamster proteins
  • You are currently taking part in another research study that involves treatments outside of normal medical care
  • You have a bleeding or clotting disorder other than hemophilia A
  • You are currently receiving immune tolerance induction treatment (a special therapy sometimes used when the body stops responding to hemophilia treatment) at the time of joining the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: (+)1-888-84 22937

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
24 January 2024
Est. completion
31 March 2028

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Occurrence of adverse events (AEs); Occurrence of Serious adverse events (SAEs); Occurrence of adverse reactions (ARs); Occurrence of Serious adverse reactions (SARs); Occurrence of adverse events of important identified risks (AESIs); Number of adverse events related to overdose; Number of adverse events related to previously taken drugs and concomitant drugs

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov